WHWK
NASDAQWhitehawk Therapeutics Inc.
SectorHealth CareIndustryBiotechnology: Pharmaceutical Preparations
Price$2.87-0.07 (-2.38%)
03:15 PM07:45 PM
News · 26 weeks56-87%
2026-04-192026-10-11
Mix2390d
- Insider13(57%)
- Other5(22%)
- SEC Filings3(13%)
- Leadership1(4%)
- Analyst1(4%)
Latest news
25 items- ANALYSTStifel initiated coverage on Whitehawk Therapeutics with a new price targetStifel initiated coverage of Whitehawk Therapeutics with a rating of Buy and set a new price target of $9.00
- PRWhitehawk Therapeutics Presents Real-World Analyses Supporting MUC16 as a Durable ADC Target in Ovarian Cancer at IGCS 2026MUC16 Expression Remained High and Stable Following Standard-of-Care Therapies, Supporting Its Potential Utility in Both Combination Approaches and Relapsed SettingsHigh MUC16 Expression Was Associated with Poor Real-World Overall Survival in High-Grade Serous Ovarian Carcinoma, the Most Common Subtype of Ovarian CancerFindings Reinforce the Scientific Rationale for HWK-016, Whitehawk's Next-Generation MUC16-Directed ADC Currently in Phase 1 DevelopmentMORRISTOWN, N.J., Oct. 1, 2026 /PRNewswire/ -- Whitehawk Therapeutics, Inc. (NASDAQ:WHWK), a clinical-stage oncology therapeutics company applying advanced technologies to established tumor biology to efficiently develop improved antibody drug
- INSIDERAmendment: SEC Form 4 filed by CHIEF FINANCIAL OFFICER Giacobello Scott M.4/A - Whitehawk Therapeutics, Inc. (0001422142) (Issuer)
- INSIDERAmendment: SEC Form 4 filed by CHIEF EXECUTIVE OFFICER Lennon David James4/A - Whitehawk Therapeutics, Inc. (0001422142) (Issuer)
- INSIDERAmendment: SEC Form 4 filed by Officer Ball Bryan4/A - Whitehawk Therapeutics, Inc. (0001422142) (Issuer)
- INSIDERAmendment: SEC Form 4 filed by Chief Scientific Officer Dornan David4/A - Whitehawk Therapeutics, Inc. (0001422142) (Issuer)
- INSIDERAmendment: SEC Form 4 filed by Chief Medical Officer Dugan Margaret4/A - Whitehawk Therapeutics, Inc. (0001422142) (Issuer)
- INSIDERSEC Form 4 filed by CHIEF EXECUTIVE OFFICER Lennon David James4 - Whitehawk Therapeutics, Inc. (0001422142) (Issuer)
- INSIDERSEC Form 4 filed by CHIEF FINANCIAL OFFICER Giacobello Scott M.4 - Whitehawk Therapeutics, Inc. (0001422142) (Issuer)
- INSIDERSEC Form 4 filed by Chief Medical Officer Dugan Margaret4 - Whitehawk Therapeutics, Inc. (0001422142) (Issuer)
- INSIDERSEC Form 4 filed by Chief Scientific Officer Dornan David4 - Whitehawk Therapeutics, Inc. (0001422142) (Issuer)
- INSIDERSEC Form 4 filed by Officer Ball Bryan4 - Whitehawk Therapeutics, Inc. (0001422142) (Issuer)
- PRWhitehawk Therapeutics Presents Real-World Analyses Supporting PTK7 as a Durable ADC Target in EGFR Wild-Type Non-Small Cell Lung Cancer at WCLC 2026PTK7 Expression Remained Stable Following Standard-of-Care Therapies, Supporting Its Relevance as a Target in Second- or Later-Line EGFR NSCLCFindings Reinforce the Scientific Rationale for HWK-007, Whitehawk's Next-Generation PTK7-Directed ADC Currently in Phase 1 DevelopmentMORRISTOWN, N.J., Sept. 13, 2026 /PRNewswire/ -- Whitehawk Therapeutics, Inc. (NASDAQ:WHWK), a clinical-stage oncology therapeutics company applying advanced technologies to established tumor biology to efficiently develop improved antibody drug conjugate (ADC) cancer treatments, today announced the presentation of two real-world analyses supporting protein tyrosine kinase 7 (PTK7) as a durable and clinically relevant A
- INSIDERSEC Form 4 filed by Director Iyengar Vijay K4 - Whitehawk Therapeutics, Inc. (0001422142) (Issuer)
- INSIDERSEC Form 3 filed by new insider Iyengar Vijay K3 - Whitehawk Therapeutics, Inc. (0001422142) (Issuer)
- SECSEC Form 8-K filed by Whitehawk Therapeutics Inc.8-K - Whitehawk Therapeutics, Inc. (0001422142) (Filer)
- PRWhitehawk Therapeutics Appoints Vijay Iyengar, MD, to Board of DirectorsFormer Incyte Executive Brings Extensive Oncology, Corporate Strategy, Business Development and Medical Affairs ExperienceMORRISTOWN, N.J., Sept. 10, 2026 /PRNewswire/ -- Whitehawk Therapeutics, Inc. (NASDAQ:WHWK), a clinical-stage oncology therapeutics company applying advanced technologies to established tumor biology to efficiently develop improved antibody-drug conjugate (ADC) cancer treatments, today announced the appointment of Vijay Iyengar, MD, to its Board of Directors, effective September 9, 2026.Dr. Iyengar brings more than two decades of oncology experience building and scaling global businesses, leading strategic transactions across development-stage and commercial assets and gu
- PRWhitehawk Therapeutics to Participate in Upcoming Investor ConferencesMORRISTOWN, N.J., Sept. 2, 2026 /PRNewswire/ -- Whitehawk Therapeutics, Inc. (NASDAQ:WHWK), a clinical-stage oncology therapeutics company applying advanced technologies to established tumor biology to efficiently develop improved antibody drug conjugate (ADC) cancer treatments, today announced participation at the following investor conferences:Cantor Global Healthcare Conference 2026 – management will participate in investor meetings on September 9, 2026. Wells Fargo 21st Annual Healthcare Conference – management will participate in investor meetings on September 10, 2026. Morgan Stanley 24th Annual Global Healthcare Conference – management will participate in investor meetings, and Scott
- SECAmendment: SEC Form SCHEDULE 13G/A filed by Whitehawk Therapeutics Inc.SCHEDULE 13G/A - Whitehawk Therapeutics, Inc. (0001422142) (Subject)
- SECSEC Form 10-Q filed by Whitehawk Therapeutics Inc.10-Q - Whitehawk Therapeutics, Inc. (0001422142) (Filer)
- SECWhitehawk Therapeutics Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits8-K - Whitehawk Therapeutics, Inc. (0001422142) (Filer)
- PRWhitehawk Therapeutics Reports Second Quarter 2026 Financial Results and Recent HighlightsPhase 1 trials for HWK-007 and HWK-016 continue to enroll; the Phase 1 trial for HWK-206 is on track to initiate in Q3 2026Cash, cash equivalents and short-term investments of $190.0 million as of June 30, 2026, anticipated to fund operations into 2H 2028MORRISTOWN, N.J., Aug. 6, 2026 /PRNewswire/ -- Whitehawk Therapeutics, Inc. (NASDAQ:WHWK), a clinical-stage oncology therapeutics company applying advanced technologies to established tumor biology to efficiently deliver improved antibody drug conjugate (ADC) cancer treatments, today announced financial results for the quarter ended June 30, 2026, and provided recent corporate highlights."The second quarter saw meaningful progress for our th
- INSIDERDirector Dalal Anupam was granted 1,275,510 shares (SEC Form 4)4 - Whitehawk Therapeutics, Inc. (0001422142) (Issuer)
- ANALYSTLeerink Partners initiated coverage on Whitehawk Therapeutics with a new price targetLeerink Partners initiated coverage of Whitehawk Therapeutics with a rating of Outperform and set a new price target of $9.00
- PRBiocytogen and Whitehawk Therapeutics Enter Global Collaboration for Bispecific Antibody ADC DevelopmentBiocytogen (SSE: 688796; HKEX: 02315) and Whitehawk Therapeutics, Inc. (("Whitehawk, NASDAQ:WHWK) today announced a global collaboration to develop bispecific antibody-drug conjugates (BsADC). Biocytogen will provide access to up to five bispecific antibodies using its proprietary RenLite® platform, and Whitehawk will evaluate these in combination with its ADC linker-payload platform technologies. Whitehawk then has the option to advance any resulting BsADC candidates as part of its pipeline. Based on a common light-chain design, RenLite® supports the discovery, screening, and optimization of fully human bispecific antibodies across diverse target combinations, while reducing the risk of
WHWK FAQ
5 questionsWhere does WHWK stock trade?
Whitehawk Therapeutics Inc. (WHWK) is listed on NASDAQ.What sector and industry is WHWK in?
Whitehawk Therapeutics Inc. operates in the Health Care sector, Biotechnology: Pharmaceutical Preparations industry.What are analysts saying about WHWK?
Whitehawk Therapeutics Inc. has had 4 recent analyst actions on file. The most recent action was from Stifel: Buy with a $900.00 price target on 2026-10-01. Recent price targets range from $600.00 to $1000.00.What companies are similar to WHWK?
Notable peers in the same industry include LLY (Eli Lilly and Company), JNJ (Johnson & Johnson), ABBV (AbbVie Inc.), MRK (Merck & Company Inc.), NVS (Novartis AG). Compare WHWK side-by-side with any of them on Quantisnow.How can I track WHWK on Quantisnow?
Quantisnow aggregates Whitehawk Therapeutics Inc.'s SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow WHWK to receive live email and push alerts on every new disclosure.